Gentium S.p.A (GENT)
-NasdaqGM | Prev Close: | 8.49 |
|---|
| Open: | N/A |
|---|
| Bid: | 4.98 x 200 |
|---|
| Ask: | 10.00 x 100 |
|---|
| 1y Target Est: | 14.00 |
|---|
| Beta: | 1.13 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 6.96 - 12.84 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 26,348 |
|---|
| Market Cap: | 127.98M |
|---|
| P/E (ttm): | 42.03 |
|---|
| EPS (ttm): | 0.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Q1 2013 Gentium SpA Earnings Release - 07:00 am ETCCBN(Tue, May 14)
- Gentium Reports First Quarter Financial ResultsGlobeNewswire(Tue, May 14)
- Why Are These 3 European Stocks Attracting Institutional Buyers?at Seeking Alpha(Thu, May 9)
- Is The Bad News Already Priced In For These 5 Short Squeeze Picks?at Seeking Alpha(Tue, Apr 23)
- Oversold Conditions For Gentium SpA (GENT)at TheStreet(Thu, Apr 18)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, Apr 16)
- Gentium to Request Re-Examination of CHMP Opinion on DefibrotideGlobeNewswire(Tue, Apr 16)
- Satellite Symposia on Defibrotide and Veno-Occlusive Disease at EBMT 39th Annual MeetingGlobeNewswire(Tue, Apr 9)
- GENTIUM S.P.A. FinancialsEDGAR Online Financials(Fri, Apr 5)
- Gentium Announces Resignation of Board MemberGlobeNewswire(Thu, Mar 28)
- Gentium Reports Fourth Quarter and Year End 2012 Financial ResultsGlobeNewswire(Thu, Mar 28)
- Q4 and Year-End 2012 GENTIUM SPA Earnings Release - Time Not SuppliedCCBN(Thu, Mar 28)
- Gentium S.p.A Earnings: What Investors Should Watchat Wall St. Cheat Sheet(Wed, Mar 27)
- CHMP Negative on Gentium CandidateZacks(Tue, Mar 26)
- Gentium Announces Initiation of Phase 1 study in JapanGlobeNewswire(Tue, Mar 26)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| GENT | 0.00% | 127.98M |
| NVO | 0.00% | 91.49B |
| TEVA | 0.00% | 33.65B |
| AGN | 0.00% | 29.04B |
| FRX | 0.00% | 10.53B |
Key Statistics
| Forward P/E (1 yr): | 6.96 |
|---|
| P/S (ttm): | 3.14 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.56 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.10 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Gentium S.p.A., a biopharmaceutical company, engages in the research and development of drugs derived from DNA and DNA molecules. The company develops and manufactures defibrotide, an investigational drug based on a mixture of single-and double-st...
View More 
0.08%